{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:24:52Z","timestamp":1758860692050},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Environmental Management"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.jenvman.2006.07.005","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T15:18:44Z","timestamp":1158679124000},"page":"1-8","source":"Crossref","is-referenced-by-count":2,"title":["Economics of \u201cessential use exemptions\u201d for metered-dose inhalers under the Montreal Protocol"],"prefix":"10.1016","volume":"85","author":[{"given":"Stephen J.","family":"DeCanio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine S.","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jenvman.2006.07.005_bib1","unstructured":"Asthma Therapy Coalition, 2004. Re: Comments Regarding Citizen Petition Submitted by US Stakeholders Group on MDI Transition (Docket # 2003P-0029), letter to Dockets Management Branch from Edward John Allera and Jodi Finder, April 7, 2004."},{"key":"10.1016\/j.jenvman.2006.07.005_bib2","series-title":"Ozone Connections: Expert Networks in Global Environmental Governance","author":"Canan","year":"2002"},{"issue":"7","key":"10.1016\/j.jenvman.2006.07.005_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1046\/j.1525-1497.2000.08014.x","article-title":"A physician survey of the effect of drug sample availability on physicians\u2019 behavior","volume":"15","author":"Chew","year":"2000","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jenvman.2006.07.005_bib4","unstructured":"Connolly, C., Allen, M., 2005. Medicare Drug Benefit May Cost $1.2 Trillion. Washington Post (9 February 2005): A01."},{"issue":"3","key":"10.1016\/j.jenvman.2006.07.005_bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/cep\/byi028","article-title":"Economics of the \u2018Critical Use\u2019 of methyl bromide under the Montreal Protocol","volume":"23","author":"DeCanio","year":"2005","journal-title":"Contemporary Economic Policy"},{"issue":"4","key":"10.1016\/j.jenvman.2006.07.005_bib7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1162\/003465399558391","article-title":"Tax avoidance and the deadweight loss of the income tax","volume":"81","author":"Feldstein","year":"1999","journal-title":"The Review of Economics and Statistics"},{"key":"10.1016\/j.jenvman.2006.07.005_bib8","unstructured":"Honeywell, 2004. Re: Comments regarding citizen petition submitted by the US stakeholders group on MDI transition (Docket Number 03P-0020), letter to Dockets Management Branch from Steven H. Bernhardt, Ph.D. (April 20, 2004)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib9","unstructured":"International Pharmaceutical Aerosol Consortium (IPAC), 2005. IPAC Submission to the Medical Aerosols Technical Options Committee: Transition to CFC-Free Metered-Dost Inhalers (28 March 2005)."},{"issue":"S26","key":"10.1016\/j.jenvman.2006.07.005_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ppul.70037","article-title":"HFA inhalers","volume":"37","author":"Koninck","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1016\/j.jenvman.2006.07.005_bib11","first-page":"42","article-title":"Sample medication dispensing in a residency practice","volume":"34","author":"Morelli","year":"1992","journal-title":"Journal of Family Practice"},{"key":"10.1016\/j.jenvman.2006.07.005_bib12","unstructured":"National Economic Research Associates, 2004. Economic Issues Raised in the FDA's Proposed Rule on Removing the Essential-Use Designation for Albuterol MDIs, by Richard P. Rozek and Emily R. Bishko, Comments submitted to the US Food and Drug Administration [Docket No. 2003 P-0029] (August 13 2004)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib13","unstructured":"National Economic Research Associates, 2005. Factors that Improve Patient Access After Removing the Essential-Use Designation for Albuterol CFC MDIs, by Richard P. Rozek and Emily R. Bishko, Supplemental Comments submitted to the US Food and Drug Administration [Docket No. 2003P-0029] (February 18 2005)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib14","unstructured":"Natural Resources Defense Council (NRDC), 2004a. Re: Depletion of the Stratospheric Ozone Layer, letter to Michael O. Leavitt, Administrator, Environmental Protection Agency, from David Doniger (May 13 2004a)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib15","unstructured":"Natural Resources Defense Council (NRDC), 2004b. RE: Docket No. 03P-0029: Rulemaking on the Non-Essentiality of Albuterol Metered Dose Inhalers (MDIs), letter to Division of Dockets Management, Food and Drug Administration, from David Doniger (May 20 2004b)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib16","unstructured":"Natural Resources Defense Council (NRDC), 2004c. RE: Docket No. 03P-0029: Proposed Rule on the Non-Essentiality of Albuterol Metered Dose Inhalers (MDIs); Installation and Commissioning of New CFC Production Capacity by Honeywell,\u201d letter to Division of Dockets Management from David Doniger (October 20, 2004c)."},{"issue":"5","key":"10.1016\/j.jenvman.2006.07.005_bib17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/A:1020992803400","article-title":"Tax deductions and the marginal welfare cost of taxation","volume":"9","author":"Parry","year":"2002","journal-title":"International Tax and Public Finance"},{"issue":"3","key":"10.1016\/j.jenvman.2006.07.005_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1331\/154434504323064039","article-title":"Disposition of pharmaceutical samples from a private medical clinic","volume":"44","author":"Peterson","year":"2004","journal-title":"Journal of the American Pharmacists Association"},{"key":"10.1016\/j.jenvman.2006.07.005_bib19","unstructured":"Pollack, A., 2006. The Higher Cost of Breathing. The New York Times (May 12, 2006)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib20","unstructured":"Stein, S.W., Stefely, J.S., 2003. Reinventing Metered Dose Inhalers: From Poorly Efficient CFC MDIs to Highly Efficient HFA MDIs. Drug Delivery Technology 3, No. 1 (January\/February 2003)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib21","unstructured":"Technology and Economic Assessment Panel (TEAP), 2001. Handbook on Essential Use Nominations."},{"key":"10.1016\/j.jenvman.2006.07.005_bib22","unstructured":"Technology and Economic Assessment Panel (TEAP), 2005. Report of the UNEP Technology and Economic Assessment Panel: May 2005 Progress Report."},{"issue":"4","key":"10.1016\/j.jenvman.2006.07.005_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1081\/JAS-200057888","article-title":"Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma","volume":"42","author":"Thongngarm","year":"2005","journal-title":"Journal of Asthma"},{"key":"10.1016\/j.jenvman.2006.07.005_bib24","unstructured":"US Environmental Protection Agency (US EPA), 2005. United States\u2019 Nomination of The Aerosol Metered Dose Inhaler (MDI) As An Essential Use, letter from Claudia A. McMurray, Deputy Assistant Secretary for Environment, to Mr. Marco Gonz\u00e1lez, Executive Secretary, Ozone Secretariat (February 2, 2005)."},{"issue":"142","key":"10.1016\/j.jenvman.2006.07.005_bib25","first-page":"48370","article-title":"Use of ozone-depleting substances; essential-use determinations, 21 CFR Part 2","volume":"67","year":"2002","journal-title":"Federal Register"},{"issue":"115","key":"10.1016\/j.jenvman.2006.07.005_bib26","first-page":"33602","article-title":"Use of ozone-depleting substances; removal of essential-use designations, 21 CFR Part 2","volume":"69","year":"2004","journal-title":"Federal Register"},{"issue":"63","key":"10.1016\/j.jenvman.2006.07.005_bib27","first-page":"17168","article-title":"Use of ozone-depleting substances; removal of essential-use designations, 21 CFR Part 2","volume":"70","year":"2005","journal-title":"Federal Register"},{"key":"10.1016\/j.jenvman.2006.07.005_bib28","unstructured":"US Stakeholders Group on MDI Transition, 2004. Comments of the US Stakeholders Group on MDI Transition, to the Notice of Proposed Rulemaking on the Non-Essentiality of CFC-Containing Single Moiety Albuterol MDIs, FDA Docket No. 003P-0029 (August 16, 2004)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib29","unstructured":"US Stakeholders Group on MDI Transition, 2005. Letter to Co-Chairs, UNEP Medical Aerosols Technical Options Committee (April 1, 2005)."},{"key":"10.1016\/j.jenvman.2006.07.005_bib30","first-page":"361","article-title":"Are sample medicines hurting the uninsured?","volume":"15","author":"Zweifler","year":"2002","journal-title":"Journal of American Board Family Practice"}],"container-title":["Journal of Environmental Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301479706002039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301479706002039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,13]],"date-time":"2019-01-13T03:51:06Z","timestamp":1547351466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301479706002039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0301479706002039"],"URL":"https:\/\/doi.org\/10.1016\/j.jenvman.2006.07.005","relation":{},"ISSN":["0301-4797"],"issn-type":[{"value":"0301-4797","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}